大阪大学病院における医薬品等の一般競争入札公告（令和8年1月21日）
令和8年1月21日|p.85
左の本文を選ぶと、右側の官報原文画像で該当箇所を照合できます。
A Q Aflibercept (Genetical Recombination) (8mg/0.07ml/1syringe) 830 syringes
A R Faricimab (Genetical Recombination) (21.0mg/0.175ml/1syringe) 270 syringes
A S Denosumab (Genetical Recombination) (120mg/1.0ml/1syringe) 540 syringes
(4) Delivery period : By 1 April, 2026 through 31 March, 2027
(5) Delivery place : The University of Osaka Hospital and Dental Hospital
(6) Qualifications for participating in the tendering procedures : Suppliers eligible for participating in the proposed tender are those who shall :
A not come under Article 7 and 8 of the Regulation concerning the Contract for The University of Osaka,
B have the Grade A or Grade B qualification during fiscal 2026 in the Kinki area in sales of product for participating in tenders by Single qualification for every ministry and agency, or in tenders by The University of Osaka,
C prove to have obtained the first-class license for selling drugs in accordance with the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices.
D prove to have the ability to deliver the products, required by this notice, on the date and to the place specified by President.
(7) Time limit of tender : 12:00 23 March, 2026
(8) Contact point for the notice : MATSUO Takenori, Procurement Section, Accounting Division, The University of Osaka Hospital, 2-15 Yamadaoka Suita shi Osaka 565-0871 Japan, TEL 06-6879-5134
(9) Please be noted that if it is indicated that environmental conditions relating to the procurement are laid down in its tender documents.